Original Webinar Date: 03/30/2023

NGS in advanced breast cancer: exploring recent clinical advancements

Learn more about breast cancer management with NGS. We explore the potential utility of complementary solid tumor and liquid biopsy testing in informing treatment decisions, as well as patient management strategies in the post CDK4/6 inhibitor therapy setting.
Speakers Calvin Chao, MD
SVP of Medical Affairs, Tempus

Cynthia Ma, MD, PhD
Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center

Massimo Cristofanilli, MD, FACP
Chief, Breast Medical Oncology, Sandra Edward Meyer Cancer Center at Weill Cornell Medicine

Related Content

View more
  • post image

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • post image

    Using TIME to accelerate trial enrollment for Aadi Bioscience

    The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.

    Read more
  • post image

    Increasing PTS using multimodal data

    Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.

    Watch replay